Long-Term Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease, a Multinational Observational Database Cohort Study
Edeltraut Garbe,1 Fabian Hoti,2 Tania Schink,1 Kristian Svendsen,3 Haydar Al-Eid,4 Per Arkhammar,5 Marie Carlholm,6 Harald Fjällbrant,6 Stefan Franzén,7,8 Cecilia Hedlund,9 Bianca Kollhorst,10 Atul Kumar,11 Muriel Lobier,2 Vasili Mushnikov,2 Tore Persson,9 Xu Qiao,2 Aaro Salosensaari,12 Wiebke Sch...
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Dove Press
2024
|
Subjects: | |
Online Access: | https://www.dovepress.com/long-term-safety-of-roflumilast-in-patients-with-chronic-obstructive-p-peer-reviewed-fulltext-article-COPD |
id |
ftdovepress:oai:dovepress.com/95090 |
---|---|
record_format |
openpolar |
spelling |
ftdovepress:oai:dovepress.com/95090 2024-09-09T20:14:15+00:00 Long-Term Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease, a Multinational Observational Database Cohort Study Garbe,Edeltraut Hoti,Fabian Schink,Tania Svendsen,Kristian Al-Eid,Haydar Arkhammar,Per Carlholm,Marie Fjällbrant,Harald Franzén,Stefan Hedlund,Cecilia Kollhorst,Bianca Kumar,Atul Lobier,Muriel Mushnikov,Vasili Persson,Tore Qiao,Xu Salosensaari,Aaro Schäfer,Wiebke Sicignano,Nicholas Johansson,Gunnar Dareng,Eileen 2024-08-21 text/html https://www.dovepress.com/long-term-safety-of-roflumilast-in-patients-with-chronic-obstructive-p-peer-reviewed-fulltext-article-COPD en eng Dove Press info:eu-repo/semantics/altIdentifier/doi/10.2147/COPD.S465517 https://www.dovepress.com/long-term-safety-of-roflumilast-in-patients-with-chronic-obstructive-p-peer-reviewed-fulltext-article-COPD info:eu-repo/semantics/openAccess International Journal of Chronic Obstructive Pulmonary Disease Original Research info:eu-repo/semantics/article 2024 ftdovepress https://doi.org/10.2147/COPD.S465517 2024-08-27T14:05:07Z Edeltraut Garbe,1 Fabian Hoti,2 Tania Schink,1 Kristian Svendsen,3 Haydar Al-Eid,4 Per Arkhammar,5 Marie Carlholm,6 Harald Fjällbrant,6 Stefan Franzén,7,8 Cecilia Hedlund,9 Bianca Kollhorst,10 Atul Kumar,11 Muriel Lobier,2 Vasili Mushnikov,2 Tore Persson,9 Xu Qiao,2 Aaro Salosensaari,12 Wiebke Schäfer,1 Nicholas M Sicignano,13 Gunnar Johansson,14 Eileen O Dareng15 1Department Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; 2Biostatistics, Scientific Services, Real World Solutions, IQVIA, Espoo, Finland; 3Department of Pharmacy, UiT The Arctic University of Norway, Tromsø, Norway; 4United States Navy, Naval Medical Center, Portsmouth, Virginia, USA; 5Global Patient Safety Biopharma, AstraZeneca, Gothenburg, Sweden; 6Late-Stage Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden; 7BPM Evidence Statistics, Medical Evidence, BioPharmaceuticals Medical, Gothenburg, Sweden; 8School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 9Biometrics, Late-stage Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden; 10Department Biometry and Data Management, Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; 11Global Patient Safety Biopharma, AstraZeneca, Bangalore, India; 12Biostatistics, Scientific Services, Real World Solutions, IQVIA, Turku, Finland; 13Health ResearchTx LLC, Trevose, Pennsylvania, USA; 14Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden; 15Safety Epidemiology and Risk Management, AstraZeneca, Cambridge, UKCorrespondence: Eileen O Dareng, AstraZeneca, City House, 126-130 Hills Road, Cambridge, CB2 1RY, United Kingdom, Tel +44 7789447801, Email eileen.dareng@astrazeneca.comPurpose: This study evaluated the long-term safety of roflumilast in patients with chronic obstructive pulmonary disease ... Article in Journal/Newspaper Arctic University of Norway UiT The Arctic University of Norway Dove Medical Press Arctic Gunnar ENVELOPE(-108.885,-108.885,59.384,59.384) Norway Persson ENVELOPE(-58.400,-58.400,-64.200,-64.200) |
institution |
Open Polar |
collection |
Dove Medical Press |
op_collection_id |
ftdovepress |
language |
English |
topic |
International Journal of Chronic Obstructive Pulmonary Disease |
spellingShingle |
International Journal of Chronic Obstructive Pulmonary Disease Garbe,Edeltraut Hoti,Fabian Schink,Tania Svendsen,Kristian Al-Eid,Haydar Arkhammar,Per Carlholm,Marie Fjällbrant,Harald Franzén,Stefan Hedlund,Cecilia Kollhorst,Bianca Kumar,Atul Lobier,Muriel Mushnikov,Vasili Persson,Tore Qiao,Xu Salosensaari,Aaro Schäfer,Wiebke Sicignano,Nicholas Johansson,Gunnar Dareng,Eileen Long-Term Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease, a Multinational Observational Database Cohort Study |
topic_facet |
International Journal of Chronic Obstructive Pulmonary Disease |
description |
Edeltraut Garbe,1 Fabian Hoti,2 Tania Schink,1 Kristian Svendsen,3 Haydar Al-Eid,4 Per Arkhammar,5 Marie Carlholm,6 Harald Fjällbrant,6 Stefan Franzén,7,8 Cecilia Hedlund,9 Bianca Kollhorst,10 Atul Kumar,11 Muriel Lobier,2 Vasili Mushnikov,2 Tore Persson,9 Xu Qiao,2 Aaro Salosensaari,12 Wiebke Schäfer,1 Nicholas M Sicignano,13 Gunnar Johansson,14 Eileen O Dareng15 1Department Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; 2Biostatistics, Scientific Services, Real World Solutions, IQVIA, Espoo, Finland; 3Department of Pharmacy, UiT The Arctic University of Norway, Tromsø, Norway; 4United States Navy, Naval Medical Center, Portsmouth, Virginia, USA; 5Global Patient Safety Biopharma, AstraZeneca, Gothenburg, Sweden; 6Late-Stage Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden; 7BPM Evidence Statistics, Medical Evidence, BioPharmaceuticals Medical, Gothenburg, Sweden; 8School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 9Biometrics, Late-stage Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden; 10Department Biometry and Data Management, Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; 11Global Patient Safety Biopharma, AstraZeneca, Bangalore, India; 12Biostatistics, Scientific Services, Real World Solutions, IQVIA, Turku, Finland; 13Health ResearchTx LLC, Trevose, Pennsylvania, USA; 14Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden; 15Safety Epidemiology and Risk Management, AstraZeneca, Cambridge, UKCorrespondence: Eileen O Dareng, AstraZeneca, City House, 126-130 Hills Road, Cambridge, CB2 1RY, United Kingdom, Tel +44 7789447801, Email eileen.dareng@astrazeneca.comPurpose: This study evaluated the long-term safety of roflumilast in patients with chronic obstructive pulmonary disease ... |
format |
Article in Journal/Newspaper |
author |
Garbe,Edeltraut Hoti,Fabian Schink,Tania Svendsen,Kristian Al-Eid,Haydar Arkhammar,Per Carlholm,Marie Fjällbrant,Harald Franzén,Stefan Hedlund,Cecilia Kollhorst,Bianca Kumar,Atul Lobier,Muriel Mushnikov,Vasili Persson,Tore Qiao,Xu Salosensaari,Aaro Schäfer,Wiebke Sicignano,Nicholas Johansson,Gunnar Dareng,Eileen |
author_facet |
Garbe,Edeltraut Hoti,Fabian Schink,Tania Svendsen,Kristian Al-Eid,Haydar Arkhammar,Per Carlholm,Marie Fjällbrant,Harald Franzén,Stefan Hedlund,Cecilia Kollhorst,Bianca Kumar,Atul Lobier,Muriel Mushnikov,Vasili Persson,Tore Qiao,Xu Salosensaari,Aaro Schäfer,Wiebke Sicignano,Nicholas Johansson,Gunnar Dareng,Eileen |
author_sort |
Garbe,Edeltraut |
title |
Long-Term Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease, a Multinational Observational Database Cohort Study |
title_short |
Long-Term Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease, a Multinational Observational Database Cohort Study |
title_full |
Long-Term Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease, a Multinational Observational Database Cohort Study |
title_fullStr |
Long-Term Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease, a Multinational Observational Database Cohort Study |
title_full_unstemmed |
Long-Term Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease, a Multinational Observational Database Cohort Study |
title_sort |
long-term safety of roflumilast in patients with chronic obstructive pulmonary disease, a multinational observational database cohort study |
publisher |
Dove Press |
publishDate |
2024 |
url |
https://www.dovepress.com/long-term-safety-of-roflumilast-in-patients-with-chronic-obstructive-p-peer-reviewed-fulltext-article-COPD |
long_lat |
ENVELOPE(-108.885,-108.885,59.384,59.384) ENVELOPE(-58.400,-58.400,-64.200,-64.200) |
geographic |
Arctic Gunnar Norway Persson |
geographic_facet |
Arctic Gunnar Norway Persson |
genre |
Arctic University of Norway UiT The Arctic University of Norway |
genre_facet |
Arctic University of Norway UiT The Arctic University of Norway |
op_relation |
info:eu-repo/semantics/altIdentifier/doi/10.2147/COPD.S465517 https://www.dovepress.com/long-term-safety-of-roflumilast-in-patients-with-chronic-obstructive-p-peer-reviewed-fulltext-article-COPD |
op_rights |
info:eu-repo/semantics/openAccess |
op_doi |
https://doi.org/10.2147/COPD.S465517 |
_version_ |
1809815955998507008 |